[CAS NO. 128253-32-7] (S)-Veliflapon
PRODUCTS SPECIFICATIONS [128253-32-7]
DESCRIPTION [128253-32-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 361.43 |
| Molecular Formula | C23H23NO3 |
| SMILES | O=C(O)[C@@H](C1CCCC1)C(C=C2)=CC=C2OCC3=NC4=CC=CC=C4C=C3 |
Summary
(S)-Veliflapon ((S)-BAY X 1005; (S)-DG-031) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP) . (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC 50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood [1] [2] [3] .
In Vitro
(S)-Viliflapon decreases leukotriene B4 (LTB4) synthesis in human whole blood with dose-dependent manner [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
References
- [1] Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95.
- [2] Hermann, David J., et al. Dosing schedules of leukotriene synthesis inhibitors for human therapy. World Intellectual Property Organization. WO2009002746.
- [3] Helgadottir, et al. Polymorphisms in the susceptibility genes for myocardial infarction, stroke, and peripheral artery occlusive disease and their use in risk assessment and prophylaxis therapy. United States. US20070280917.